secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alpha Teknova, Inc. (TKNO)
CIK:        0001850902
Form:       8-K
Filed at:   2021-08-11T23:59:59+00:00
Accession:  0001193125-21-243358
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alpha Teknova Q2 2021 revenue up 38% to $8.3M; net loss of $2.3M vs prior-year profit
--------------------------------------------------------------------------------

- Total revenue $8.3M, +38% YoY; Lab Essentials revenue $6.5M (+46%), Clinical Solutions $1.6M (+32%).
- Gross margin fell to 40.4% from 57.4%; cost of sales included $0.7M one-time reserve for excess Sample Transport inventory.
- Net loss attributable to common stockholders $2.3M ($0.52/share) vs net income of $0.1M ($0.02/share) in Q2 2020.
- Adjusted EBITDA negative $1.5M vs positive $1.2M a year ago; cash position $108M after $99.1M IPO net proceeds.
- Began construction on new GMP facility in Hollister, CA; appointed three new independent directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850902/000119312521243358/0001193125-21-243358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850902/000119312521243358/d192651d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-243358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer